StemCells Inc. (STEM)
-NasdaqCM 1.77 
0.05(2.91%) 4:00PM EDT
| Prev Close: | 1.72 |
|---|
| Open: | 1.72 |
|---|
| Bid: | 1.74 x 200 |
|---|
| Ask: | 1.80 x 7500 |
|---|
| 1y Target Est: | 3.31 |
|---|
| Beta: | 2.2 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 1.71 - 1.77 |
|---|
| 52wk Range: | 0.62 - 2.67 |
|---|
| Volume: | 344,539 |
|---|
| Avg Vol (3m): | 312,730 |
|---|
| Market Cap: | 68.99M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.76 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- STEMCELLS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhibitsEDGAR Online(Mon, Jun 10)
- StemCells, Inc. Strengthens Product Development Team and Appoints Executive to Focus on Scientific and Strategic AlliancesGlobeNewswire(Mon, Jun 10)
- 4 Healthcare Stock Stories Attracting Attention Todayat Wall St. Cheat Sheet(Tue, Jun 4)
- StemCells, Inc. Secures $30 Million Financing Commitment From Lincoln Park CapitalGlobeNewswire(Tue, Jun 4)
- STEMCELLS INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Tue, Jun 4)
- StemCells, Inc.'s Spinal Cord Injury Trial Approved by Health CanadaGlobeNewswire(Mon, Jun 3)
- Cloning: A Stem Cell Revolution?at Motley Fool(Sun, May 19)
- STEMCELLS INC FinancialsEDGAR Online Financials(Fri, May 17)
- STEMCELLS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- StemCells, Inc. Earnings Call scheduled for 4:30 pm ET todayCCBN(Thu, May 9)
- StemCells, Inc. Reports First Quarter 2013 Financial Results and Provides Business UpdateGlobeNewswire(Thu, May 9)
- STEMCELLS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Thu, May 9)
- StemCells, Inc. Announces Webcast to Discuss First Quarter 2013 Financial Results and Business UpdateGlobeNewswire(Tue, May 7)
- StemCells Inc: CEO Martin McGlynn Is Building A Blockbuster Companyat Seeking Alpha(Thu, May 2)
- StemCells, Inc. Adds Byers Eye Institute at Stanford as Second Site for Phase I/II Clinical Trial in Dry Age-Related Macular DegenerationGlobeNewswire(Thu, Apr 18)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 66.51 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.65 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.16 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery primarily in the United States.
View More